Scienture Holdings, INC 10-Q quarterly reports

Scienture Holdings, Inc. (f/k/a TRxADE HEALTH, INC.) filed its Form 10-Q for the quarter ended June 30, 2026, detailing revenue growth from ARBLI commercialization and ongoing R&D efforts, while addressing liquidity concerns.

Scienture Holdings, Inc. reported increased revenues from its new pharmaceutical product SCN-102 but continued to post significant net losses and faces substantial doubt about its ability to continue as a going concern.

Scienture Holdings, Inc. reports a substantial net loss and critical cash shortage, raising going concern doubts despite a strategic pivot to specialty pharmaceuticals and a recent FDA approval.

Scienture Holdings, formerly TRxADE Health, announces its Q1 2025 financial results amidst strategic divestitures and a focus on branded pharmaceutical development.

Scienture Holdings, formerly TRxADE Health, reported its Q3 2024 results, highlighting a period of significant strategic changes including acquisitions, divestitures, and a name change.

TRxADE HEALTH, INC. reports a net income of $19.4 million for the six months ended June 30, 2024, primarily driven by gains from discontinued operations, while facing challenges in its continuing operations.

TRxADE HEALTH, INC. reports a net income of $21.2 million for Q1 2024, driven by strategic divestitures, despite a loss from continuing operations.

TRxADE HEALTH, INC. reported its third quarter 2023 results, highlighted by the completion of the Superlatus merger, but also noted significant losses and concerns about its ability to continue as a going concern.